Novacyt (AIM:NCYT) - Stock Price, News & Analysis

NCYT Stock Overview

NCYT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Los beneficios han disminuido en 12.1% al año en los últimos 5 años.

No tiene una capitalización bursátil significativa (£57M)

Novacyt S.A. Competitors

Arecor Therapeutics

AIM:AREC

UK£44.4m

OptiBiotix Health

AIM:OPTI

UK£18.9m

Oncimmune Holdings

AIM:ONC

UK£15.4m

Tissue Regenix Group

AIM:TRX

UK£43.3m

Price History & Performance

Summary of all time highs, changes and price drops for Novacyt
Historical stock prices
Current Share Price	€0.44
52 Week High	€0.86
52 Week Low	€0.36
Beta	-1.71
1 Month Change	1.20%
3 Month Change	-21.75%
1 Year Change	-19.33%
3 Year Change	-89.13%
5 Year Change	92.39%
Change since IPO	-25.63%

Recent updates

Shareholder Returns

	NCYT	GB Biotechs	GB Market
7D	-0.8%	-1.1%	-0.5%
1Y	-19.3%	-29.8%	0.4%

Rentabilidad frente al sector: NCYT superó al sector UK Biotechs , que obtuvo un rendimiento del -30.1% el año pasado.

Rentabilidad vs. Mercado: NCYT obtuvo unos resultados inferiores a los del mercado UK, que fue del -5.3% el año pasado.

Price Volatility

Is NCYT's price volatile compared to industry and market?
NCYT volatility
NCYT Average Weekly Movement	5.4%
Biotechs Industry Average Movement	7.2%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.2%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: NCYTha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: NCYTLa volatilidad semanal ha disminuido de 12% a 6% en el último año.

About the Company

Founded	Employees	CEO	Website
2006	120	James McCarthy	https://www.novacyt.com

Novacyt S.A., junto con sus filiales, ofrece pruebas de diagnóstico in vitro y molecular para una serie de enfermedades infecciosas en el Reino Unido, el resto de Europa, Estados Unidos, Asia-Pacífico, Oriente Medio y África. Opera a través de los segmentos Primer Design, Lab21 Products e IT-IS International. El segmento Primer Design diseña, fabrica y comercializa dispositivos y reactivos para pruebas moleculares qPCR en tiempo real en el ámbito de las enfermedades infecciosas.

Novacyt S.A. Fundamentals Summary

How do Novacyt's earnings and revenue compare to its market cap?
NCYT fundamental statistics
Market cap	UK£31.16m
Earnings (TTM)	-UK£25.30m
Revenue (TTM)	UK£7.87m

4.0x

P/S Ratio

-1.2x

P/E Ratio

Is NCYT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NCYT income statement (TTM)
Revenue	UK£7.87m
Cost of Revenue	UK£4.84m
Gross Profit	UK£3.03m
Other Expenses	UK£28.33m
Earnings	-UK£25.30m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.36
Gross Margin	38.51%
Net Profit Margin	-321.40%
Debt/Equity Ratio	0%

How did NCYT perform over the long term?

See historical performance and comparison

NCYT Stock Overview

Rewards

Risk Analysis

Novacyt S.A. Competitors

AIM:AREC

UK£44.4m

AIM:OPTI

UK£18.9m

AIM:ONC

UK£15.4m

AIM:TRX

UK£43.3m

Price History & Performance

Recent News & Updates

First half 2023 earnings released: UK£0.12 loss per share (vs UK£0.071 loss in 1H 2022)

New major risk - Revenue and earnings growth

Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

New minor risk - Share price stability

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Recent updates

First half 2023 earnings released: UK£0.12 loss per share (vs UK£0.071 loss in 1H 2022)

New major risk - Revenue and earnings growth

Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

New minor risk - Share price stability

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Full year 2022 earnings released: UK£0.31 loss per share (vs UK£0.14 loss in FY 2021)

Now 20% undervalued after recent price drop

Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023

Now 21% undervalued after recent price drop

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation

Now 22% undervalued after recent price drop

First half 2022 earnings released: UK£0.07 loss per share (vs UK£0.18 loss in 1H 2021)

Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022

Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022

Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays

Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay

Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK

Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings released: UK£0.14 loss per share (vs UK£1.94 profit in FY 2020)

Price target decreased to UK£4.10

Novacyt S.A. Provides Update on DHSC Dispute

Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation

CEO & Director recently bought UK£100k worth of stock

Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation

Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Price target decreased to UK£5.20

Investor sentiment improved over the past week

Novacyt S.A. Reiterate Revenue Guidance for the Full Year

Full year 2020 earnings released

Novacyt S.A. Provides Sales Guidance for the Full Year 2021

Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios

Novacyt S.A. Announces Launch of VersaLab™ Portable

Investor sentiment deteriorated over the past week

Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range

Investor sentiment improved over the past week

Novacyt S.A. Provides Earnings Guidance for the Year 2021

Investor sentiment deteriorated over the past week

New 90-day low: UK£6.84

Investor sentiment deteriorated over the past week

Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants

New 90-day high: UK£11.26

Investor sentiment improved over the past week

Novacyt S.A. Announces Board Changes

Novacyt S.A. Appoints James McCarthy as Chief Financial Officer

Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza

Investor sentiment improved over the past week

CEO & Director recently bought UK£497k worth of stock

Market pulls back on stock over the past week

Market pulls back on stock over the past week

Market bids up stock over the past week

Market pulls back on stock over the past week